60503
document
[ Therapeutic efficacy of compound Xuanju capsule on type III prostatitis ] . OBJECTIVE To evaluate the therapeutic effect of Compound Xuanju Capsule on type III prostatitis . METHODS A total of 242 patients with type III prostatitis diagnosed by the NIH criteria were randomly divided into an experimental and a control group of equal number , the former treated with Compound Xuanju Capsule + Tamsulosin Hydrochloride , and the latter with Quinolinone antibiotics + Tamsulosin and Hydrochloride , both for 6 months . After treatment , we assessed the therapeutic effects based on the NIH-CPSI scores and the improvement of relevant complications . RESULTS All the 242 patients completed the treatment . The total effectiveness rate was 77.69 % ( 94/121 ) in the experimental group , 71.56 % ( 78/109 ) in those with complications . In comparison , it was only 47.10 % ( 57/121 ) in the control group , 31.78 % ( 34/107 ) in those with complications . Both the NIH-CPSI scores and the improvement of complications were significantly higher in the experimental than in the control group ( P < 0.05 ) . CONCLUSION Compound Xuanju Capsule has a good therapeutic effect on type III prostatitis .
60504
Intervention_Pharmacological
compound Xuanju
60505
Intervention_Pharmacological
Compound Xuanju
60506
Intervention_Pharmacological
Compound Xuanju Capsule + Tamsulosin Hydrochloride
60507
Intervention_Control
Quinolinone antibiotics + Tamsulosin and Hydrochloride
60508
Intervention_Pharmacological
Compound Xuanju
60509
Outcome_Physical
therapeutic effects based on the NIH-CPSI scores
60510
Outcome_Adverse-effects
improvement of relevant complications
60511
Outcome_Other
total effectiveness rate
60512
Outcome_Physical
NIH-CPSI scores
60513
Outcome_Adverse-effects
improvement of complications
60514
Participant_Condition
type III prostatitis ]
60515
Participant_Sample-size
242 patients
60516
Participant_Condition
type III prostatitis
60517
Participant_Sample-size
242 patients